OncoCyte Corporation

Equities

OCX

US68235C2061

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:51:17 2024-04-29 am EDT			5-day change	1st Jan Change
2.54 ^USD	+2.42%		+1.76%	+2.17%

Apr. 25	OncoCyte Corporation announced that it has received $15.8 million in funding	CI
Apr. 16	Broadwood Capital, Inc. Engages with OncoCyte Corporation	CI

OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 09, 2023 at 07:05 am EST

OncoCyte Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 0.429 million compared to USD 0.067 million a year ago. Net loss was USD 6.49 million compared to USD 9.33 million a year ago. Basic loss per share was USD 0.81 compared to USD 1.62 a year ago.
For the nine months, sales was USD 1.19 million compared to USD 0.684 million a year ago. Net loss was USD 11.79 million compared to USD 27.92 million a year ago. Basic loss per share was USD 1.68 compared to USD 5.22 a year ago.

Latest news about OncoCyte Corporation

OncoCyte Corporation announced that it has received $15.8 million in funding	Apr. 24	CI
Broadwood Capital, Inc. Engages with OncoCyte Corporation	Apr. 15	CI
Sector Update: Health Care Stocks Steady Pre-Bell Friday	Apr. 12	MT
Transcript : OncoCyte Corporation, Q4 2023 Earnings Call, Apr 12, 2024	Apr. 12
OncoCyte Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
OncoCyte Agrees to $15.8 Million Private Placement of Stock, Warrants	Apr. 12	MT
Oncocyte Corporation and Bio-Rad Laboratories, Inc. Partner on Global Launch of Transplant Assay	Apr. 11	CI
OncoCyte Corporation announced that it expects to receive $15.8 million in funding	Apr. 10	CI
Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays	Dec. 06	CI
Needham Adjusts Price Target on OncoCyte to $3.60 From $4.25, Maintains Buy Rating	Nov. 09	MT
Transcript : OncoCyte Corporation, Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
OncoCyte Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
OncoCyte Corporation(NasdaqCM:OCX) dropped from S&P Global BMI Index	23-09-18	CI
Sector Update: Health Care Stocks Steady Late Afternoon	23-08-28	MT
Sector Update: Health Care Stocks Rising in Afternoon Trading	23-08-28	MT
OncoCyte Says VitaGraft Kidney Diagnostic Test to Receive Medicare, Medicaid Coverage	23-08-28	MT
Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage	23-08-28	CI
Benchmark Adjusts Price Target on OncoCyte to $5 From $9, Maintains Speculative Buy Rating	23-08-24	MT
Piper Sandler Adjusts Price Target on OncoCyte to $3.50 From $6, Keeps Neutral Rating	23-08-15	MT
Needham Adjusts OncoCyte's Price Target to $4.25 From $9, Keeps Buy Rating	23-08-10	MT
Transcript : OncoCyte Corporation, Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (OCX) ONCOCYTE CORPORATION Reports Q2 Revenue $463,000, vs. Street Est of $0.35M	23-08-10	MT
OncoCyte Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Oncocyte Corporation Announces Executive Changes	23-08-10	CI
Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients	23-07-25	CI

Chart OncoCyte Corporation

Duration

Period

More charts

Company Profile

Oncocyte Corporation is a precision diagnostics company. The Company is engaged in the development of Oncocytes tests and the acquisition of proprietary molecular technologies in the fields of oncology and transplantation. The Companyâs products include DetermaIO, VitaGraft, DetermaCNI and GraftAssure. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaIO measures the expression level of 27 selected genes, which are interpreted through the use of a proprietary algorithm (patent pending) which computes a quantitative score (IO Score) that incorporates information from the immune inflammatory infiltrates within and around the tumor. Its pipeline test, DetermaCNI, is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. VitaGraft is a blood-based solid organ transplantation monitoring test. GraftAssure is a research use only blood-based solid organ transplantation monitoring test.

Sector

Biotechnology & Medical Research

Calendar

2024-05-13 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for OncoCyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.48 USD

Average target price

4.062 USD

Spread / Average Target

+63.81%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ONCOCYTE CORPORATION	+2.17%	33.11M
VERTEX PHARMACEUTICALS INCORPORATED	-2.42%	103B
REGENERON PHARMACEUTICALS, INC.	+1.67%	95.28B
ARGENX SE	+2.13%	22.15B
BIONTECH SE	-15.77%	21.02B
GENMAB A/S	-8.24%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-13.73%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.95%	13.68B
SAREPTA THERAPEUTICS, INC.	+34.74%	12.17B

Bio Therapeutic Drugs